Sector News

Teva offers up concessions for quick EU review of Allergan deal

February 19, 2016
Life sciences

Teva may have just dodged a lengthy delay in closing its $40 billion-plus deal for Allergan’s generics business.

On Thursday, the drugmakers offered up concessions to EU regulators that they hoped would allay antitrust concerns over the transaction, which, if it closes, will bolster Teva’s position as the world’s leading generics maker. Following the submission, the body extended its deadline to rule on the deal until March 10, Bloomberg reports.

If the EU comes down in the companies’ favor, Teva and Allergan can sidestep a deeper probe into the deal that could take 90 business days. That would delay the end-of-March closing that the pair–and their investors–have been hoping for.

While the EU didn’t provide any details on the companies’ proposal, drugmakers can often win over regulators by promising to sell off units or change their behavior, Bloomberg notes.

“Both of these companies have been through this drill several times in the past and have a good understanding of how the EU will assess their overlaps, and therefore likely have a good perspective on what concessions will be needed to get clearance,” Bloomberg Intelligence analyst Jennifer Rie told the news service. “They will likely be fairly realistic in what they offer up and close to what the EU may want.”

Meanwhile, other deal-hungry knockoff makers could stand to benefit if Teva jettisons any of its assets. Top rival Mylan ($MYL)–which Teva pursued as a deal partner before jumping ship to snag Allergan’s generic offerings–could be among them, analysts have said.

But Mylan isn’t just sitting around waiting to pick up Teva’s castoffs. Last week, it inked a $7.2 billion deal for Sweden’s Meda, a tie-up that will further its ambitions in the OTC space.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).